Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort
Open Access
- 17 August 2025
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10) , 1527-1535
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.Keywords
This publication has 30 references indexed in Scilit:
- Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial SpondyloarthritisArthritis & Rheumatology, 2025
- Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review and meta-analysisClinical Rheumatology, 2024
- Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical PracticeRheumatology and Therapy, 2023
- The Clinical Characteristics of Psoriatic Arthritis: A Cross-Sectional Study Based on the Psoriatic Arthritis Cohort of West China HospitalRheumatology and Therapy, 2023
- Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World StudyDermatology and Therapy, 2022
- Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysisZeitschrift für Rheumatologie, 2021
- Updated therapies for the management of Psoriatic ArthritisClinical Immunology, 2020
- The pathogenesis of psoriatic arthritisThe Lancet, 2018
- The Epidemiology of Psoriatic ArthritisRheumatic Disease Clinics of North America, 2015
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006